Brind.

Avacta Therapeutics Announces CFO Brian Hahn and Interim Results Meeting

1 report, 1 independent Updated Oct 12
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Avacta Group plc announced an interim results investor meeting scheduled for October 15, 2026. Brian Hahn, who serves as Chief Financial Officer, and Christina Coughlin, the Chief Executive Officer, will provide a live presentation to shareholders regarding the company's performance. The presentation is open to both existing and potential shareholders.

From investegate.co.uk

Why it matters

Some supportBrind's analysis of the reports

Avacta Therapeutics is a clinical-stage life sciences company that develops targeted oncology drugs using its proprietary pre|CISION® platform. The investor meeting provides shareholders and the market insight into the progress and financial health of the company's cancer therapies.

From investegate.co.uk

Who's involved

  • Brian HahnChief Financial Officer of Avacta Therapeutics

Keep exploring

The entities involved

  • Brian Hahn

    Ph.D. University of Cambridge 1973

    Nothing else this week.

  • XDC

    Belgian cinema exhibition services company

    Nothing else this week.

Coverage

Newest first; wire copies grouped